Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -257.33% is 49% below its 5-year average of -172.81%, near the high end of its 5-year range (-427778.96%–0.00%).
5.23% above its 12-month average of -271.52%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -222.83%.
NET PROFIT MARGIN
-257.33%
NET PROFIT MARGIN AVG TTM
-271.52%
NET PROFIT MARGIN AVG 3Y
-181.58%
NET PROFIT MARGIN AVG 5Y
-172.81%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+5.23%
CURRENT VS 3Y AVG
-41.71%
CURRENT VS 5Y AVG
-48.91%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 513 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
bioAffinity Technologies, Inc.
Market Cap
$2.67M
Net Profit Margin
-257.33%
TTM Avg
-271.52%
3Y Avg
-181.58%
5Y Avg
-172.81%
Market Cap
$2.62M
Net Profit Margin
-2449.04%
TTM Avg
-339.09%
3Y Avg
-222.12%
5Y Avg
-170.97%
Market Cap
$2.52M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$2.93M
Net Profit Margin
-131.76%
TTM Avg
-396.75%
3Y Avg
-403.38%
5Y Avg
-531.17%
Market Cap
$2.38M
Net Profit Margin
-974.68%
TTM Avg
-561.03%
3Y Avg
-287.02%
5Y Avg
-224.14%
Market Cap
$2.32M
Net Profit Margin
-201355.37%
TTM Avg
-74928.77%
3Y Avg
-55011.63%
5Y Avg
-36705.99%
Market Cap
$3.04M
Net Profit Margin
-3089.55%
TTM Avg
-3099.32%
3Y Avg
-6095.20%
5Y Avg
-22555.36%
Market Cap
$2.22M
Net Profit Margin
-862.34%
TTM Avg
-747.16%
3Y Avg
-4673.17%
5Y Avg
-3945.34%
Market Cap
$3.12M
Net Profit Margin
0.00%
TTM Avg
-9993.13%
3Y Avg
-11306.74%
5Y Avg
-8768.57%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | $2.67M | -257.33% | -271.52% | -181.58% | -172.81% |
| iSpecimen Inc. (ISPC)vs › | $2.62M | -2449.04% | -339.09% | -222.12% | -170.97% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.52M | 0.00% | 0.00% | 0.00% | 0.00% |
| Jaguar Health, Inc. (JAGX)vs › | $2.93M | -131.76% | -396.75% | -403.38% | -531.17% |
| iTonic Holdings Ltd. (ITOC)vs › | $2.38M | -974.68% | -561.03% | -287.02% | -224.14% |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | -201355.37% | -74928.77% | -55011.63% | -36705.99% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.04M | -3089.55% | -3099.32% | -6095.20% | -22555.36% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.22M | -862.34% | -747.16% | -4673.17% | -3945.34% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.12M | 0.00% | -9993.13% | -11306.74% | -8768.57% |
| Aethlon Medical, Inc. (AEMD)vs › | $3.35M | 0.00% | 0.00% | -523.72% | -1138.73% |
Operating Margin
-171.6%
Net Profit Margin
-257.3%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -222.83% |
| 2026-03-31 | -268.63% |
| 2025-12-31 | -196.98% |
| 2025-09-30 | -349.30% |
| 2025-06-30 | -319.88% |
| 2025-03-31 | -143.53% |
| 2024-12-31 | -134.40% |
| 2024-09-30 | -85.13% |
| 2024-06-30 | -88.01% |
| 2024-03-31 | -81.53% |
| 2023-12-31 | -107.22% |
| 2023-09-30 | -767.51% |
| 2023-06-30 | -8816.36% |
| 2023-03-31 | -166426.71% |
| 2022-12-31 | -71380.35% |
| 2022-09-30 | -427778.96% |
| 2022-06-30 | -6742.11% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
